Literature DB >> 28331466

Generic Modified-Release Antiepileptic Drugs: No Difference Within Formulations, but Important Differences Across Formulations.

Cynthia L Harden.   

Abstract

Year:  2017        PMID： 28331466      PMCID： PMC5340552          DOI： 10.5698/1535-7511-17.1.29

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  10 in total

1.  World is ill-prepared for "inevitable" flu pandemic.

Authors: 
Journal:  Bull World Health Organ       Date:  2004-04       Impact factor: 9.408

2.  Assessing bioequivalence of generic modified-release antiepileptic drugs.

Authors:  Emily L Johnson; Yi-Ting Chang; Barbara Davit; Barry E Gidal; Gregory L Krauss
Journal:  Neurology       Date:  2016-03-25       Impact factor: 9.910

3.  Trial Reporting in ClinicalTrials.gov - The Final Rule.

Authors:  Deborah A Zarin; Tony Tse; Rebecca J Williams; Sarah Carr
Journal:  N Engl J Med       Date:  2016-09-16       Impact factor: 91.245

4.  Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.

Authors:  Michael D Privitera; Timothy E Welty; Barry E Gidal; Francisco J Diaz; Ron Krebill; Jerzy P Szaflarski; Barbara A Dworetzky; John R Pollard; Edmund J Elder; Wenlei Jiang; Xiaohui Jiang; Michel Berg
Journal:  Lancet Neurol       Date:  2016-02-12       Impact factor: 44.182

5.  Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.

Authors:  Tricia Y Ting; Wenlei Jiang; Robert Lionberger; Jessica Wong; Jace W Jones; Maureen A Kane; Allan Krumholz; Robert Temple; James E Polli
Journal:  Epilepsia       Date:  2015-07-23       Impact factor: 5.864

Review 6.  Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.

Authors:  Tom Jefferson; Mark Jones; Peter Doshi; Chris Del Mar
Journal:  BMJ       Date:  2009-12-08

7.  The imperative to share clinical study reports: recommendations from the Tamiflu experience.

Authors:  Peter Doshi; Tom Jefferson; Chris Del Mar
Journal:  PLoS Med       Date:  2012-04-10       Impact factor: 11.069

Review 8.  Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

Authors:  Tom Jefferson; Mark Jones; Peter Doshi; Elizabeth A Spencer; Igho Onakpoya; Carl J Heneghan
Journal:  BMJ       Date:  2014-04-09

9.  Cost-benefit of stockpiling drugs for influenza pandemic.

Authors:  Ran D Balicer; Michael Huerta; Nadav Davidovitch; Itamar Grotto
Journal:  Emerg Infect Dis       Date:  2005-08       Impact factor: 6.883

10.  Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza.

Authors:  Aeron C Hurt; Heath Kelly
Journal:  Emerg Infect Dis       Date:  2016-06       Impact factor: 6.883
  10 in total
  1 in total

1.  Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder.

Authors:  Maximilian Pilhatsch; Tasha Glenn; Natalie Rasgon; Martin Alda; Kemal Sagduyu; Paul Grof; Rodrigo Munoz; Wendy Marsh; Scott Monteith; Emanuel Severus; Rita Bauer; Philipp Ritter; Peter C Whybrow; Michael Bauer
Journal:  Int J Bipolar Disord       Date:  2018-05-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.